Will the UK-EU vaccine war delay lockdown lifting?
Ban on export of Covid jabs to Britain threatens to slow campaign to inoculate population
Health experts breathed a sigh of relief after the EU and UK avoided a vaccine war earlier this year when the bloc backed down on plans to restrict Covid jab exports.
But now hostilities have flared up again in the wake of a fresh threat to block doses bound for Britain while Brussels struggles to meet the EU’s shortfall.
Boris Johnson is expected to speak to his European counterparts this week in an effort to avoid further clashes that could threaten the UK’s speedy vaccination campaign.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
EU on the offensive
Defence Secretary Ben Wallace yesterday warned the European Commission that “the world is watching”, after the bloc threatened to veto exports of Oxford-AstraZeneca vaccines made by sub-contractor Helix in the Netherlands.
European Commission President Ursula von der Leyen told Germany’s Funke Media Group on Saturday that the bloc was considering “the possibility to forbid planned exports”.
“That is the message to AstraZeneca,” she said. “You fulfil your contract with Europe before you start delivering to other countries.”
But Wallace told Sky’s Sophie Ridge on Sunday that implementing such a ban would be a “very damaging thing to happen for a trading bloc that prides itself on rule of law”. The move would be “counterproductive because the one thing we know about vaccination production and manufacture is that it is collaborative”, he added.
On the opposite side of the barricades, an EU official told Reuters that while “the Brits are insisting that the Halix plant in the Netherlands must deliver the drug substance produced there to them”, the stockpile “produced in Halix has to go to the EU”.
The Leiden-based plant is listed as a supplier of vaccines “in both the contracts that AstraZeneca has signed with Britain and with the European Union”, the news agency reports.
Despite being named one of the EU’s main sources of production in a deal signed last August, the factory does not have regulatory approval to supply the bloc, the Financial Times (FT) reports.
But an internal AstraZeneca document seen by Reuters reportedly shows that the drug maker expects to secure EU approval later this week.
Meanwhile, while there are currently no outstanding requests for UK exports from the Helix production plant, “London has insisted its deal with AstraZeneca to supply the UK with 100 million doses gives it first call on production from EU plants as well as British factories”, says the FT.
Johnson is expected to phone European leaders including Emmanuel Macron and Angela Merkel this week in a bid to enlist them to oppose Brussels’ proposed expert ban, which would “push post-Brexit relations to a new low”, the paper adds.
Could a ban derail the UK’s vaccine rollout?
European Commission boss Von der Leyen said last week that the bloc was unhappy with the level of vaccine “reciprocity” between the two states. The UK has received ten million shots from Brussels so far, while the EU has “not received anything from the British”, she told reporters.
The EU is having major supply issues with AstraZeneca, which was contracted to deliver 180 million jabs to the bloc in the second quarter of this year but will now deliver less than half that amount - despite managing to fulfil its obligations to the UK government.
That said, while the spat between London and Brussels largely centres on the AstraZeneca vaccine, “most of the jabs being exported from the EU to Britain are Pfizer”, notes Politico’s London Playbook. So the extent to which a block on jabs from AstraZeneca’s Dutch plant would affect the UK’s vaccination campaign is “unclear”, the news site says.
The UK rollout is facing a separate setback, however, after AstraZeneca vaccine-maker the Serum Institute of India (SII) warned that the delivery of five million doses would be delayed.
According to an analysis for The Guardian, Downing Street’s target date for offering every UK adult at least one vaccine dose could be pushed back by two weeks as a result of the delivery delay, to 23 June.
And an export ban on all vaccinations due to be brought to the UK - including the Pfizer, Moderna and Janssen jabs - could see the target date pushed back by two months, to 27 August, the paper reports.
Even a block on the Pfizer vaccine alone could delay every adult receiving a jab until 5 August, the research by data analytics firm Airfinity suggests.
However, No. 10 has insisted that while an EU export ban could delay the speed of Britain’s vaccination programme, the government’s roadmap out of lockdown would remain largely unaffected “as it would affect only the May and June supplies, when all over-50s will have been protected”, The Times reports.
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Sorcha Bradley is a writer at The Week and a regular on “The Week Unwrapped” podcast. She worked at The Week magazine for a year and a half before taking up her current role with the digital team, where she mostly covers UK current affairs and politics. Before joining The Week, Sorcha worked at slow-news start-up Tortoise Media. She has also written for Sky News, The Sunday Times, the London Evening Standard and Grazia magazine, among other publications. She has a master’s in newspaper journalism from City, University of London, where she specialised in political journalism.
-
Who actually needs life insurance?
The Explainer If you have kids or are worried about passing on debt, the added security may be worth it
By Becca Stanek, The Week US Published
-
Sexual wellness trends to know, from products and therapies to retreats and hotels
The Week Recommends Talking about pleasure and sexual health is becoming less taboo
By Theara Coleman, The Week US Published
-
Is the AI bubble deflating?
Today's Big Question Growing skepticism and high costs prompt reconsideration
By Joel Mathis, The Week US Published
-
Nigeria's worsening rate of maternal mortality
Under the radar Economic crisis is making hospitals unaffordable, with women increasingly not receiving the care they need
By Harriet Marsden, The Week UK Published
-
Dengue hits the Americas hard and early
Speed Read Puerto Rico has declared an epidemic as dengue cases surge
By Peter Weber, The Week US Published
-
Covid four years on: have we got over the pandemic?
Today's Big Question Brits suffering from both lockdown nostalgia and collective trauma that refuses to go away
By Chas Newkey-Burden, The Week UK Published
-
How happy is Finland really?
Today's Big Question Nordic nation tops global happiness survey for seventh year in a row with 'focus on contentment over joy'
By Harriet Marsden, The Week UK Published
-
The hollow classroom
Opinion Remote school let kids down. It will take much more than extra tutoring for kids to recover.
By Mark Gimein Published
-
How Tehran became the world's nose job capital
Under the radar Iranian doctors raise alarm over low costs, weak regulation and online influence of 'Western beauty standards'
By Harriet Marsden, The Week UK Published
-
Africa's renewed battle against female genital mutilation
Under the radar Campaigners call for ban in Sierra Leone after deaths of three girls as coast-to-coast convoy prepares to depart
By Harriet Marsden, The Week UK Published
-
Excess screen time is making children only see what is in front of them
Under the radar The future is looking blurry. And very nearsighted.
By Devika Rao, The Week US Published